相似文献
1
A brief history of the treatment of viral hepatitis C.
Clin Liver Dis (Hoboken). 2012 Mar 6;1(1):6-11. doi: 10.1002/cld.1. eCollection 2012 Feb.
2
A brief history of hepatitis milestones.
Liver Int. 2014 Feb;34 Suppl 1:29-37. doi: 10.1111/liv.12409.
3
Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C.
Am J Gastroenterol. 2003 Nov;98(11):2354-62. doi: 10.1111/j.1572-0241.2003.t01-1-08735.x.
4
[The factors associated with viral relapse after interferon treatment in chronic hepatitis C patients].
Zhonghua Gan Zang Bing Za Zhi. 2006 Aug;14(8):565-8.
5
6
Progress in diagnosis of hepatitis and the cirrhotic liver.
Ann Clin Lab Sci. 1999 Apr-Jun;29(2):87-103.
7
Brief report: acute viral hepatitis and poor maternal and perinatal outcomes in pregnant Sudanese women.
J Med Virol. 2008 Oct;80(10):1747-8. doi: 10.1002/jmv.21284.
8
HCV Health Policy Developments in Response to the National Viral Hepatitis Action Plan: A Brief Update.
Soc Work Public Health. 2017 Feb 17;32(2):77-81. doi: 10.1080/19371918.2016.1188745. Epub 2016 Jul 26.
9
Viral hepatitis control in China. A brief review on the present status of viral hepatitis in China.
Chin Med J (Engl). 1992 Mar;105(3):179-82.
10
[ALAT and viral RNA as risk factors in 68 blood donors with anti-hepatitis C antibodies].
Schweiz Med Wochenschr. 1993 Jan 23;123(3):57-61.
引用本文的文献
1
Utilizing Theory of Planned Behaviour to increase intention to participate in hepatitis C treatment therapy among Methadone maintenance therapy clients (MMT) in Malaysia: A cluster randomised control trial.
PLoS One. 2025 May 22;20(5):e0324718. doi: 10.1371/journal.pone.0324718. eCollection 2025.
2
Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment.
JAMA Netw Open. 2022 Dec 1;5(12):e2246604. doi: 10.1001/jamanetworkopen.2022.46604.
3
Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review.
World J Hepatol. 2022 Mar 27;14(3):525-534. doi: 10.4254/wjh.v14.i3.525.
4
Hepatitis C Positive Organ Donation in Heart Transplantation.
Curr Transplant Rep. 2021;8(4):359-367. doi: 10.1007/s40472-021-00350-1. Epub 2021 Nov 10.
5
Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C.
Int J Gen Med. 2021 Jan 28;14:289-301. doi: 10.2147/IJGM.S283910. eCollection 2021.
6
Success of Direct-Acting, Antiviral-Based Therapy for Chronic Hepatitis C Is Not Affected by Type 2 Diabetes.
Clin Diabetes. 2020 Jan;38(1):40-46. doi: 10.2337/cd18-0112.
7
The era of first direct-acting antiviral agents: What did we learn?
Clin Liver Dis (Hoboken). 2016 Oct 2;8(3):72-75. doi: 10.1002/cld.574. eCollection 2016 Sep.
8
Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?
World J Hepatol. 2018 Sep 27;10(9):543-548. doi: 10.4254/wjh.v10.i9.543.
9
Hepatitis C in Eastern Europe and Central Asia: a survey of epidemiology, treatment access and civil society activity in eleven countries.
Hepatol Med Policy. 2017 Jun 13;2:9. doi: 10.1186/s41124-017-0026-z. eCollection 2017.
10
HIV, HCV and HBV: A Review of Parallels and Differences.
Infect Dis Ther. 2018 Dec;7(4):407-419. doi: 10.1007/s40121-018-0210-5. Epub 2018 Sep 4.
本文引用的文献
1
Response-guided telaprevir combination treatment for hepatitis C virus infection.
N Engl J Med. 2011 Sep 15;365(11):1014-24. doi: 10.1056/NEJMoa1014463.
2
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.
Hepatology. 2011 Oct;54(4):1433-44. doi: 10.1002/hep.24641. Epub 2011 Sep 26.
3
Boceprevir for previously treated chronic HCV genotype 1 infection.
N Engl J Med. 2011 Mar 31;364(13):1207-17. doi: 10.1056/NEJMoa1009482.
4
Boceprevir for untreated chronic HCV genotype 1 infection.
N Engl J Med. 2011 Mar 31;364(13):1195-206. doi: 10.1056/NEJMoa1010494.
5
Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.
Clin Infect Dis. 2011 Apr 1;52(7):889-900. doi: 10.1093/cid/cir076.
6
New insights into structure and replication of the hepatitis C virus and clinical implications.
Semin Liver Dis. 2010 Nov;30(4):333-47. doi: 10.1055/s-0030-1267535. Epub 2010 Oct 19.
7
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
Lancet. 2010 Aug 28;376(9742):705-16. doi: 10.1016/S0140-6736(10)60934-8. Epub 2010 Aug 6.
8
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.
Gastroenterology. 2010 Nov;139(5):1593-601. doi: 10.1053/j.gastro.2010.07.009. Epub 2010 Jul 14.
9
Telaprevir for previously treated chronic HCV infection.
N Engl J Med. 2010 Apr 8;362(14):1292-303. doi: 10.1056/NEJMoa0908014.
10
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
N Engl J Med. 2009 Apr 30;360(18):1839-50. doi: 10.1056/NEJMoa0807650.
Zotero 插件